Superior benefits of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors for diabetic kidney disease: A cohort study
This study shows the superior cardiorenal benefits of SGLT-2is compared with DPP-4is in the DKD population, regardless of concomitant antidiabetic agents or time from DKD onset to study drug initiation. SGLT-2is should be prioritized in adult patients with DKD.
Authors
- Hsiao‐Ling Chen (ORCID: https://orcid.org/0000-0001-7544-2178)
- I‐Ting Wang (ORCID: https://orcid.org/0000-0002-4626-4592)
- Hao‐Min Cheng (ORCID: https://orcid.org/0000-0002-3885-6600)
- Yi‐Wen Tsai (ORCID: https://orcid.org/0000-0003-1422-7217)
- Chen‐Huan Chen (ORCID: https://orcid.org/0000-0002-9262-0287)
- Chern‐En Chiang
- Y.H. Lee
Institutions
- National Yang Ming Chiao Tung University (TW)
- Taipei Veterans General Hospital (TW)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1111/dom.15998
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.72